Drugs / GDC-1261
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07567846 | Apr 2026 → Nov 2027 expected | metastatic prostate carcinoma | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-1261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07567846 ↗ |